Search results: (10000)
News Long-term Benefit of Sotorasib for Survival of Patients with Pre-treated Advanced/Metastatic NSCLC with G12C Mutation of KRAS Oncogene
Sotorasib is indicated as monotherapy for advanced non-small-cell lung cancer (NSCLC) with the KRASG12C gene mutation, if there has been progression after ≥ 1 prior line of systemic therapy. The 2-year analysis of data from the CodeBreaK 100 study published in April 2023 demonstrated the long-term benefit of sotorasib for this patient population in terms of progression-free survival (PFS) and overall survival (OS), regardless of programmed death-ligand 1 (PD-L1) receptor expression, including patients with a poor prognosis. In the Czech Republic, sotorasib has been reimbursed by public health insurance for this indication since September 2023.
News Is It Necessary to Discontinue Dupilumab in Patients with Atopic Dermatitis During the COVID-19 Pandemic?
Italian authors described their experiences with remote treatment of 200 atopic dermatitis (AD) patients using dupilumab during the COVID-19 pandemic outbreak in spring 2020. Observations from clinical practice, published data, and pathophysiological considerations do not suggest an increased risk of SARS-CoV-2 infection in AD patients receiving this biological treatment.
News Efficacy and Safety of Preservative-Free Latanoprost in the Treatment of Open-Angle Glaucoma and Elevated Intraocular Pressure – Results of a Meta-Analysis
Many eye drops for the treatment of glaucoma still contain preservatives today. However, these can cause eye irritation, so non-preservative formulations should be preferred. The following meta-analysis compared the efficacy and safety of antiglaucoma medications with and without preservatives.
News What Did the Patent for the Synthesis of Highly Purified Trazodone Bring?
Trazodone is a modern antidepressant that is used in the treatment of various types of depression, including those accompanied by anxiety, sleep disorders, or sexual dysfunction. Angelini's invention, with patent protection valid until 2028, presents several methods for the preparation of purified trazodone, or trazodone hydrochloride, which guarantees high purity of this substance and a low content of unwanted residues.
News The Benefit of Liposomal Irinotecan in the Treatment of Pancreatic Cancer in a Young Patient – A Case Study
Pancreatic tumors continue to be a challenge in modern oncology. Due to the asymptomatic nature of early stages, most cases are diagnosed in advanced stages. The five-year survival rate of patients does not even reach 10%, and up to half of patients with metastatic pancreatic cancer never make it to the second line of systemic therapy due to the rapid deterioration of their overall clinical condition. In a case study from her own practice, Dr. Marie Beneš Kočová from the Oncology Department of České Budějovice Hospital shared her experience with the treatment of a relatively early-detected disease in a young patient.
News Long-term Safety of Dupilumab in Adult Patients with Moderate to Severe Atopic Dermatitis
Moderate to severe atopic dermatitis (AD) often requires systemic therapy. The long-term safety of dupilumab in patients with this condition was evaluated in an open-label extension (OLE) of the LIBERTY AD study, the results of which were recently published.
News CASE STUDIES on the topic of progressing interstitial lung processes
This page serves as a hub for case studies on the topic of progressing interstitial processes. The case studies aim to provide a multidisciplinary view on the rare disease topic of IPP.
News How does Benzalkonium Chloride and Prostaglandins Affect Meibomian Gland Epithelial Cells?
Benzalkonium chloride is commonly used in eye drops intended for glaucoma treatment due to its preservative effect. However, in recent years, it has been shown to cause damage to both superficial and deeper eye tissues and also provoke other difficulties. The study presented below examined its effect on the epithelium of the Meibomian glands.
News The main advantage of sartans is a very good safety profile. Now it is about increasing adherence in hypertensive patients
The rules for initiating hypertension treatment have been simplified. The trend is to achieve blood pressure control as early as possible, making it unnecessary to wait for a longer period for the effect of non-pharmacological measures. One of the 4 main classes of antihypertensives is AT1 receptor blockers for angiotensin II – sartans, which bring several advantages. These include a low incidence of side effects, a good antihypertensive effect, or the possibility of use in fixed combinations. We will take a closer look at the current position of sartans in the treatment of hypertension with Assoc. Prof. Ondřej Petrák, MD, PhD, from the Center for Research, Diagnosis, and Treatment of Hypertension at the 3rd Internal Clinic - Clinic of Endocrinology and Metabolism at the 1st Faculty of Medicine, Charles University in Prague, and General University Hospital in Prague.
News Intravenous Thrombolysis in Ischemic Stroke Patients on Dabigatran Treatment
What are the outcomes of performing intravenous thrombolysis in patients with acute ischemic stroke after reversing the anticoagulant effect of dabigatran with idarucizumab? The answer is provided by a data analysis from real-world clinical practice in stroke centers, published by Czech authors.
News Development and Benefits of Intestinal Gel LECIG for Patients with Parkinson's Disease
Patients with advanced Parkinson's disease, for whom the current regimen of orally and transdermally administered medications is insufficient for symptom relief, now have a new treatment option. It involves the continuous administration of an intestinal gel that combines three effective antiparkinsonian drugs.
News Neuraxpharm Introduces a New Form of Medical Cannabis
Since November 2022, a new medication containing an active full-spectrum cannabis extract – Naxiva Panaxol from Neuraxpharm – has been available in the Czech Republic. The cannabis extract is offered in collaboration with Panaxia Labs Israel. Both companies are key players in the European medical cannabis market. Their agreement ensures the distribution of these products not only in the Czech Republic but also in Switzerland and Germany.
News Efficacy of Luspatercept in 1st Line Treatment of Anemia Due to Low-Risk Myelodysplastic Syndrome
A planned interim analysis of the COMMANDS study showed a greater benefit of the innovative treatment with luspatercept compared to the established treatment with epoetin alfa in patients with anemia due to low-risk myelodysplastic syndrome (MDS) and untreated with erythropoiesis-stimulating agents (ESA). The results were published in June 2023 in the journal Lancet.
News Long-term Benefit of Luspatercept Therapy – Fresh Data from the MEDALIST Study
The goal of therapy for low-risk myelodysplastic syndrome (MDS) is to compensate for anemia, improve or maintain quality of life, and prolong the time to progression to higher-risk MDS (HR-MDS) or acute myeloid leukemia (AML). To manage anemia, we can resort to transfusion therapy or administer epoetins, lenalidomide, or luspatercept, the first representative of a class of drugs that support erythrocyte maturation. Last year's data from the follow-up of patients enrolled in the MEDALIST study pertain specifically to the latter.
News Effect of Luspatercept Treatment in Patients with MDS/MPN-RS-T
The presented post hoc analysis of the MEDALIST study demonstrates the effect and good tolerance of luspatercept in the rare disease from the myelodysplasia group − MDS/MPN-RS-T.
News Early Effect of Once-a-Day Trazodone in the Treatment of Major Depressive Disorder
Most antidepressants have a delayed onset of action, reaching therapeutically effective levels only several weeks after the start of treatment. Trazodone is characterized by a specific mechanism of action and a rapid onset of therapeutic effect. A newly published analysis evaluated the available clinical data regarding the early effect of once-a-day trazodone in patients with Major Depressive Disorder (MDD).
News Effect of Extended-Release Metformin on Cognitive Functions in Older Frail Women with Diabetes and Hypertension
Women have a higher risk of geriatric frailty regardless of age and menopausal status. This risk further increases with the presence of diabetes and hypertension, which also elevate the risk of cognitive dysfunction. According to available data, metformin may reduce the risk of developing frailty in postmenopausal women. A recently published Italian study, LEOPARDESS, aimed to evaluate the effect of extended-release metformin on the cognitive functions of this population of women.
News Augmentation of Clozapine with Lurasidone in Resistant Schizophrenia in Real Practice
Treatment-resistant schizophrenia remains a clinical and pharmacological challenge. Clozapine remains the gold standard in these cases. Unfortunately, a significant portion of patients respond only partially to it. The solution is often an augmentation strategy with another atypical antipsychotic. According to current findings, adjunctive therapy with lurasidone appears promising — two recently published studies have brought interesting data.
News Prostate Health Index and its Possible Use in Clinical Practice
With the increasing incidence of prostate cancer, the effort to improve its diagnostics is also growing. The exclusively used and practice-proven prostate-specific antigen (PSA) continues to play an indispensable role in identifying at-risk patients, but some of its isoforms can also provide important information for deciding the patient's further fate. Based on their combination, a so-called prostate health index (PHI) can be determined. A recently published work by Czech authors assessed the usability of PHI as a parameter suitable for evaluating the aggressiveness of prostate cancer (PC) within the PHIMOPLUKTHOM study.
News Long-term survival of a 50-year-old man with metastatic pancreatic cancer on a combination of nal-IRI + 5-FU/LV in 2nd line treatment − case study
A recently published case study from the Czech Republic describes a patient with progression of pancreatic cancer following surgical treatment and adjuvant chemotherapy, who achieved a one-year survival with good quality of life on a combination of nal-IRI + 5-FU/LV after the failure of gemcitabine + nab-paclitaxel in the 1st line of palliative treatment.
News Hypotension during treatment with sacubitril/valsartan: practical tips for prevention and management
Despite the undeniable benefits of sacubitril/valsartan in terms of morbidity and mortality in patients with chronic heart failure, its administration can be complicated by side effects. The most common of these is hypotension. Although it is an unpleasant complication, it does not – and should not – always be a reason to discontinue therapy. Fear of hypotension should not lead to not prescribing sacubitril/valsartan at all. We provide practical guidance on how to approach this clinical situation.
News Experiences with Long-term Treatment of Psoriasis with Interleukin 17A Inhibitor
The current publication of the long-term extension of the UNCOVER-3 study, which focused on the treatment of psoriasis with ixekizumab, describes the efficacy and safety of 4 years of use of this drug.